Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giordano Cecchetti

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Alzheimer'S Research & Therapy|May 22, 2026
Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies eraFederico Coraglia, Giordano Cecchetti, Giulia Rugarli, et al.
Seizure|November 14, 2025
Cytotoxic lesions of the corpus callosum related to epilepsy or anti-seizure medications: a systematic reviewGianni Cutillo, Guido Bonelli, Martina Rubin, et al.
Neuroimage. Clinical|June 7, 2021
Resting-state electroencephalographic biomarkers of Alzheimer's diseaseGiordano Cecchetti, Federica Agosta, Silvia Basaia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 13, 2017
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging caseAlberto Andrea Zambon, Giordano Cecchetti, Francesca Caso, et al.
Journal of Alzheimer'S Disease : JAD|September 3, 2016
Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease DementiaSalvatore Mazzeo, Roberto Santangelo, Maria Paola Bernasconi, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2017
Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's DiseaseRoberto Santangelo, Giordano Cecchetti, Maria Paola Bernasconi, et al.
The Lancet Regional Health. Europe|July 2, 2026
From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid TherapyMassimo Filippi, Giordano Cecchetti, Alma Ghirelli, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersGiulia Rugarli, Giordano Cecchetti, Roberto Santangelo, et al.
Journal of Neurology|October 15, 2022
Brain structural abnormalities and cognitive changes in a patient with 17q21.31 microduplication and early onset dementia: a case reportMichela Leocadi, Elisa Canu, Camilla Cividini, et al.
Neurology|January 2, 2024
EEG Correlates in the 3 Variants of Primary Progressive AphasiaGiordano Cecchetti, Silvia Basaia, Elisa Canu, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Alzheimer'S Research & Therapy|May 22, 2026
Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies eraFederico Coraglia, Giordano Cecchetti, Giulia Rugarli, et al.
Seizure|November 14, 2025
Cytotoxic lesions of the corpus callosum related to epilepsy or anti-seizure medications: a systematic reviewGianni Cutillo, Guido Bonelli, Martina Rubin, et al.
Neuroimage. Clinical|June 7, 2021
Resting-state electroencephalographic biomarkers of Alzheimer's diseaseGiordano Cecchetti, Federica Agosta, Silvia Basaia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 13, 2017
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging caseAlberto Andrea Zambon, Giordano Cecchetti, Francesca Caso, et al.
Journal of Alzheimer'S Disease : JAD|September 3, 2016
Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease DementiaSalvatore Mazzeo, Roberto Santangelo, Maria Paola Bernasconi, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2017
Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's DiseaseRoberto Santangelo, Giordano Cecchetti, Maria Paola Bernasconi, et al.
The Lancet Regional Health. Europe|July 2, 2026
From Target Engagement to Treatment Governance: The Evolving Role of Amyloid PET in Anti-Amyloid TherapyMassimo Filippi, Giordano Cecchetti, Alma Ghirelli, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersGiulia Rugarli, Giordano Cecchetti, Roberto Santangelo, et al.
Journal of Neurology|October 15, 2022
Brain structural abnormalities and cognitive changes in a patient with 17q21.31 microduplication and early onset dementia: a case reportMichela Leocadi, Elisa Canu, Camilla Cividini, et al.
Neurology|January 2, 2024
EEG Correlates in the 3 Variants of Primary Progressive AphasiaGiordano Cecchetti, Silvia Basaia, Elisa Canu, et al.
Pageof 5